Novartis receives FDA warning
June 6, 2013Manufacturing and Production, Sales and Marketing CGMP, FDA, GMP, Novartis
The FDA has castigated Novartis for what it calls ‘significant violations’ of current good manufacturing practice (CGMP) regulations for finished …
PAN makes series of appointments and promotions
June 6, 2013Medical Communications Pan, agency, comms
Creative comms agency PAN has bolstered its team with two new arrivals and three promotions. Vanessa Hume has joined the …
Mirna appoints ex-Pfizer senior director
June 6, 2013Manufacturing and Production, Research and Development, Sales and Marketing Pfizer, miRNA
Biotech firm Mirna Therapeutics has appointed Dr Sinil Kim as vice president of Oncology and chief medical officer. Kim will …
Bayer takes over Conceptus
June 6, 2013Sales and Marketing Bayer, Conceptus
The Bayer Group, which contains Bayer HealthCare, has taken over US contraception specialist Conceptus in a $1.1 billion deal. The …
Aveo to cut workforce after FDA knock-back
June 6, 2013Research and Development, Sales and Marketing Aveo, FDA, cuts, tivozanib
Aveo will make major jobs cuts this year after news that a kidney cancer licence for its oncology drug tivozanib …
J&J recalls 32 million contraceptive packs
June 5, 2013Manufacturing and Production Cilest, J&J, JJ, recall
Johnson & Johnson has announced a 43-country recall of its oral contraceptive Cilest and suspended production of the drug because …
Novartis drug shows cancer promise
June 5, 2013Research and Development, Sales and Marketing ASCO, Cancer, Novartis
A Novartis drug which has been given breakthrough therapy designation by the FDA has demonstrated early promise in patients with …
Celgene predicts trio of blockbusters
June 5, 2013Sales and Marketing Celgene, Pomalidomide, Revlamid, Velcade
Europe’s medicines committee the CHMP has just adopted a positive opinion for Celgene’s new multiple myeloma treatment Pomalidomide Celgene (pomalidomide). …
HAVAS LYNX makes several leadership changes
June 5, 2013Medical Communications, Sales and Marketing Creative Lynx, HAVAS LYNX, PM Society Digital Awards
Comms agency HAVAS LYNX has realigned its senior team making a number of changes for the global firm as it …
GSK licences RA drug
June 5, 2013Research and Development, Sales and Marketing GSK, RA, morphosys
GlaxoSmithKline is gambling millions of euros on an investigational drug in a bid to get an edge in the fight …
AstraZeneca abandons late-stage RA drug
June 5, 2013Research and Development, Sales and Marketing AstraZeneca, RA, Rigel
AstraZeneca is to exit development of a new rheumatoid arthritis drug, after Phase III trials produced disappointing results.The Anglo-Swedish firm …
AstraZeneca/BMS drug granted speedy FDA review
June 5, 2013Sales and Marketing AstraZeneca, BMS, lipodystrophy
AstraZeneca and partner Bristol-Myers Squibb have been granted a priority review for their rare disease drug metreleptin. The medicine is …
Sanofi admits $285m failure
June 4, 2013Research and Development, Sales and Marketing Sanofi, its benzamide iniparib, otamixaban
Sanofi has consigned two investigational drugs to the corporate dustbin, preferring a $285 million dent in its coffers to continuing …
USP delays guidance on elemental impurities
June 4, 2013Manufacturing and Production Q3D, USP
The US Pharmacopeial Convention (USP) has agreed to postpone the deadline for implementing two new chapters on elemental impurities in …
NSCLC lift for Boehringer
June 4, 2013Research and Development, Sales and Marketing Boehringer, NSCLC
Boehringer’s pipeline has been boosted with the news that its investigational oral triple angiokinase inhibitor nintedanib plus chemotherapy, extends the …
Boehringer and Lilly launch diabetes game
June 4, 2013Medical Communications Boehringer Ingelheim, combat, lilly
Boehringer Ingelheim and Eli Lilly have launched an educational digital game for type 2 diabetes called Complications Combat. The game …
Vocera appoints president and chief executive
June 4, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Brent Lang, Vocera
Healthcare comms firm Vocera Communications has announced Brent Lang’s appointment as president and chief executive officer to the firm and …
UK government cautious on trial transparency
June 4, 2013Research and Development, Sales and Marketing Goldacre, UK, alltrials, transparency
Two ministers with responsibility for life sciences in the UK struck a cautious note over clinical trial transparency at an …
SHL attends the 2013 Japan PDA
June 4, 2013Manufacturing and Production auto injectors, autoinjector, autoinjectors, japan pda. shl pda
SHL once again had the honor of being invited to participate and speak at the PDA Japan 2013 (日本PDA製薬å¦ä¼š), which …
Promising signs for Novartis’ lung cancer drug
June 4, 2013Sales and Marketing ALK+, ASCO, LDK378, NSCLC, Novartis
Targeted lung cancer treatment LDK378 has been shown to help patients with the ALK+ gene mutation in a phase I trial.Novartis’ drug …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
